Vis enkel innførsel

dc.contributor.authorDeyab, Gia
dc.contributor.authorReine, Trine M.
dc.contributor.authorVuong, Tram Thu
dc.contributor.authorJenssen, Trond Geir
dc.contributor.authorHjeltnes, Gunnbjørg
dc.contributor.authorAgewall, Stefan
dc.contributor.authorMikkelsen, Knut
dc.contributor.authorFørre, Øystein
dc.contributor.authorFagerland, Morten
dc.contributor.authorKolset, Svein Olav
dc.contributor.authorHollan, Ivana
dc.date.accessioned2022-02-16T07:31:21Z
dc.date.available2022-02-16T07:31:21Z
dc.date.issued2021-07-09
dc.description.abstractThe endothelial glycocalyx (EG) is essential for proper function of the endothelium and for vascular integrity, but its role in premature atherogenesis in rheumatoid arthritis (RA) has not been studied yet. EG impairment can play a role in pathogenesis of vascular disease, and one of its characteristics is shedding of syndecan-1 from endothelial cells. Syndecan-1 shedding is mediated by matrix metalloproteinase-9 (MMP-9) and counteracted by tissue inhibitor of metalloproteinases (TIMP)-1. Cardiovascular disease risk in RA is reversible by disease modifying antirheumatic drugs (DMARDs), but the exact modes of action are still unclear. Therefore, we examined effects of DMARDs on syndecan-1, MMP-9 and TIMP-1 in RA patients, and searched for associations between these parameters and inflammatory activity. From the observational PSARA study, we examined 39 patients starting with methotrexate (MTX) monotherapy (in MTX naïve patients, n = 19) or tumor necrosis factor inhibitors (TNFi) in combination with MTX (in MTX non-responders, n = 20) due to active RA. Serum syndecan-1, MMP-9 and TIMP-1 were measured at baseline and after six weeks of treatment. Serum syndecan-1 (p = 0.008) and TIMP-1 (p<0.001) levels decreased after six weeks of anti-rheumatic treatment. Levels of MMP-9 also decreased, but the difference was not statistically significant. The improvement in syndecan-1 levels were independent of changes in inflammatory activity. There was no significant difference in changes in syndecan-1 levels from baseline to 6 weeks between the MTX and TNFi groups, however the change was significant within the MTX group. Six weeks of antirheumatic treatment was associated with reduction in serum levels of syndecan-1, which might reflect reduced syndecan-1 shedding from EG. Thus, it is possible that EG-preserving properties of DMARDs might contribute to their cardioprotective effects. These effects may be at least partly independent of their anti-inflammatory actions. Our findings do not support the notion that syndecan-1 shedding in RA is mediated mainly by increased MMP-9 or decreased TIMP-9 serum concentration.en_US
dc.identifier.citationDeyab, Reine, Vuong, Jenssen, Hjeltnes G, Agewall, Mikkelsen, Førre, Fagerland, Kolset SO, Hollan. Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis. PLOS ONE. 2021;16(7):e0253247en_US
dc.identifier.cristinIDFRIDAID 1977717
dc.identifier.doi10.1371/journal.pone.0253247
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/10037/24061
dc.language.isoengen_US
dc.publisherPublic Library of Scienceen_US
dc.relation.journalPLOS ONE
dc.relation.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270157/pdf/pone.0253247.pdf
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.titleAntirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritisen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail
Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel